AHA 2020 This subanalysis of THALES showed that ticagrelor in combination with aspirin significantly reduced the 30-day risk of stroke or death compared to aspirin in high-risk patients with ipsilateral atherosclerotic stenosis.
AHA 2020 The SOLOIST-WHF and the SCORED trials revealed some novel observations with the SGLT1 and SGLT2 inhibitor sotagliflozin in diabetes patients after acute HF and in diabetes patients with CKD.
ESC 2020 During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes.
ESC 2020 Prof. Kirchhof shares the findings of the EAST-AF NET 4 trial, which evaluated the effect of early rhythm control in patients who were recently diagnosed with AF compared to usual care.
This comparative cohort study used data from clinical practice from 13 countries. Results showed that initiation of SGLT2i vs. DPP-4i in adults with T2DM was associated with lower risks of HF, death, MI and stroke.
T2DM patients who developed HF alone or in combination with stroke, CKD or PAD had the highest 5-year risk of death and the greatest decrease in lifespan when compared with development of other CV and renal diseases.
In the THALES trial, a combination of ticagrelor and aspirin reduced the composite endpoint of recurrent stroke or death in patients with stroke or TIA, but increased severe bleeding.
This retrospective cohort study used longitudinal data from 4 European health care databases to compare the risk of major bleeding in DOAC and VKA users with nonvalvular atrial fibrillation (NVAF).
Treatment with the GLP-1RA dulaglutide for a median of 5.4 years resulted in a reduction of cognitive impairment compared to placebo in T2DM patients ≥50 years, in an exploratory analysis of REWIND.
This analysis of the REGARDS study showed that AF patients without CV comorbidities had no increased risk of stroke compared to individuals without AF or CV comorbidities.
A survey conducted by the ESC among cardiologists and CV nurses revealed that 78.8% of responders perceived a decrease in STEMI admissions since the beginning of the COVID-19 outbreak.
P2Y12i monotherapy reduces risk of MI, but not of stroke, all cause death, vascular death and bleeding, compared to aspirin monotherapy, in patients with established atherosclerosis.